Sign inJoin waitlistJoin the waitlist

Geoffrey Gorse

Physician · SLUcare Physician Group

Credentials: · · · · · ·

History

SLUcare Physician Group
2022–Present

University of California
1980–1982
University of California
1977–1980
David Geffen Sch of Med at UCLA
1973–1977

Research

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The…
The Journal of Infectious Diseases · 1996 · 387 citations
Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial
JAMA · 1999 · 330 citations
Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older
The Journal of Infectious Diseases · 2009 · Last of 5 authors · 329 citations

RB
Robert Belshe
44 papers
Michael Keefer
21 papers
Juliana McElrath
17 papers
Lawrence Corey
13 papers
Peter Wright
13 papers
RD
Raphael Dolin
12 papers
Sharon Frey
12 papers
AN
Ann-Christine Nyquist
9 papers
CG
Cynthia Gibert
9 papers
LR
Lewis Radonovich
9 papers
MB
Mary Bessesen
9 papers
Michael Simberkoff
9 papers

Grants

Clinical Impact of Human Coronaviruses and Viral Diversity
Department of Veterans Affairs · I01
Contact PI · St. Louis Va Medical Center
2009–2013

Clinical trials

The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)
Principal investigator · Unknown · Phase 1
Nova Immunotherapeutics Limited
2015–2020
MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
Principal investigator · Withdrawn · Phase 1, Phase 2
US Department of Veterans Affairs
2012–2014
Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults
Study chair · Completed · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)
2007–2008
Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults
Study chair · Completed · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)
2005